Yihai Cao, PhD, Prof, born in Shandong, China, received his medical training at the Medical School, Shandong University in 1983. 1983-1986, he received further basic and clinical training from the Chinese Academy of Medical Sciences and from the Ludwig Institute for Cancer Research, Switzerland. He obtained his Ph.D. degree in 1993 from the Karolinska Institutet, followed by a 3-yr postdoctoral training period at the Harvard Medical School, Children's Hospital (Dr. Judah Folkman´s Laboratory), Boston, Massachusetts, USA. He returned to the Karolinska Institutet in 1996 and became a full professor in 2004. He received a honorary medical degree (M.D.) from Copenhagen University, Denmark, 2006. He is currently a guest professor at the Linköping University, Sweden. He received the Fernstrom research prize. In 2010, Dr Cao received the distinguished professor award at the Karolinska Institutet. Dr. Cao also received the ERC-advanced research grant award for being the top scientist in Europe. His research interests include molecular mechanisms of pathological angiogenesis that contributes to obesity, metabolic diseases, diabetic complications, cancer, metastasis, and cardiovascular diseases, with emphasis on clinical relevance and translational research. He has published more than 160 research articles.

Jonathan Hepple, Ph D, Venture investor in life science companies since 1998. Founder of Rosetta Capital, a leading international secondary venture firm, focused on life sciences. Rosetta's investments include Enobia Pharmaceuticals, GeminX Pharmaceuticals, Cytochroma, Forward Pharma and Zealand Pharmaceuticals. Also Partner at Seroba Kernel Life Sciences, a European venture firm, investing in biotech and medtech. Current board seats include Axelar AB, Clanotech AB, Covagen AG and Opsona Therapeutics.

ClanoTech AB • c/o M Lindblom • Feroxgatan 11 • S-170 67 Solna • Sweden • Org. nr. 556706-6658 • Registered office: Solna